

THE THIRTEENTH MEETING OF
THE SOUTH-EAST ASIA REGIONAL
MDR-TB ADVISORY COMMITTEE
(SEA RGLC)

2-4 FEBRUARY 2021

A decorative graphic consisting of several parallel diagonal lines in a light blue-grey color, extending from the bottom left towards the top right of the page.

SEA/TB/373

© *World Health Organization 2021*

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO license

(CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this license, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the license shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation: The Thirteenth Meeting of the South-East Asia Regional MDR-TB Advisory Committee (SEA RGLC). License: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Table of Contents

Acronyms	v
Background	1
Opening Session.....	2
Technical Sessions.....	3
Day 1: Presentations from high-burden countries	3
Discussions – Day 1	16
Day 2 (i): Technical updates	18
Day 2 (ii): Partner presentations	25
Discussions – Day 2	30
Day 3 (i): Regional progress updates	32
Day 3 (ii): rGLC planning for 2021	37
Overall priorities for 2021	37
Recommendations and action points	39
Recommendations to the SEAR Member States	39
Action points for the rGLC committee	40
Action points for the rGLC secretariat	41
Annex 1: Agenda of the meeting	42
Annex 2: List of Participants.....	45

Acronyms

aDSM	active TB drug safety monitoring and management
Am	amikacin
Bdq	bedaquiline
BEAT-TB	Building Evidence for Advance Treatment against Tuberculosis
BPaL	(regimen comprising of) bedaquiline, pretomanid and linezolid
C&DST	culture and drug susceptibility testing
CDC	Centers for Disease Control and Prevention, Atlanta, USA
Cfz	clofazimine
Cs	cycloserine
DAT	Digital Adherence Technologies
Dlm	delamanid
DNA	deoxyribonucleic acid
DOT	directly observed treatment
DR-TB	drug-resistant tuberculosis
DST	drug susceptibility test
DS-TB	drug susceptible TB
E	ethambutol
Eto	ethionamide
FQ	fluoroquinolones
EQA	external quality assessment
GF	the Global Fund
GDF	Stop TB Partnership's Global Drug Facility
GDI	Global Drug-resistant Tuberculosis Initiative
GX	GeneXpert
HC	health centre
H _{HD}	isoniazid <small>high dose</small>
KNCV	Royal Dutch Tuberculosis Association
Lfx	levofloxacin
LPA	line probe assay test
Lzd	linezolid
MDR-TB	multidrug-resistant tuberculosis
Mfx _{HD}	moxifloxacin <small>high dose</small>
MoH	Ministry of Health
MoU	Memorandum of Understanding
NAAT	nucleic acid amplification test
NGS	Next Generation Sequencing

NRL	National Reference Laboratories
NSP	National Strategic Plan
NTP	National Tuberculosis Control Programme
NTRL	national tuberculosis reference laboratory
OR	Operational Research
PCR	polymerase chain reaction
PMDT	programmatic management of drug-resistant tuberculosis
PPM	public private mix
PV	pharmacovigilance
rGLC	Regional Green Light Committee
RR-TB	rifampicin-resistant tuberculosis
R&R	recording and reporting
SEAR	South-East Asia Region
SLD	second-line TB drugs
SLI	second-line TB injectable
SNPs	single nucleotide polymorphisms
SNRL	supranational reference laboratory
STR	shorter treatment regimen (for RR-/MDR-TB) (if prefixed by “m”, it means modified STR)
TA	technical assistance
TB	tuberculosis
TPT	TB preventive treatment
TWG	technical working group
UHC	universal health coverage
UN	United Nations
VOT	virtual/video observed therapy
WGS	whole-genome sequencing
XDR-TB	extensively drug-resistant tuberculosis
Z	pyrazinamide

Background

The WHO South-East Asia Region (SEAR) accounts for an estimated 171 000 rifampicin-resistant tuberculosis (RR-TB) and multidrug-resistant tuberculosis (MDR-TB) cases emerging each year (WHO Global TB Report 2020). There has been a steady improvement in screening and enrolment of drug-resistant TB (DR-TB) patients with 70 120 RR-/MDR-TB enrolled on treatment in 2019. However, a slight decline in extensively drug-resistant tuberculosis (XDR-TB) enrolment to 2 008 patients was seen in the same year. The treatment success rate for RR-/MDR-TB patients remained at 52%, similar to earlier cohorts, and the treatment success for XDR-TB patients was only 37%.

The SEA Regional Green Light Committee (rGLC) has been undertaking technical assistance, capacity building and programme review missions in Member States. This has been a major challenge in 2020 due to the COVID-19 pandemic related travel restrictions that have been imposed.

The rGLC annual meeting provides an opportunity to review the mission reports and discuss the findings collectively, in light of the global recommendations that will help identify key areas to be worked on in the coming year.

The thirteenth meeting of the SEA rGLC (also called the “MDR-TB advisory committee”) was held virtually from 2 to 4 February 2021. Participation was invited from 11 rGLC members, MDR-TB focal points from national programmes of six high-burden countries and Nepal, the Global Fund, Stop TB Partnership’s Global Drug Facility (GDF), Stop TB Partnership and the US Agency for International Development (USAID). Out of the 11 members and one standing invitee, ten participated in the meeting for all three days, while one member could attend only for two days. The list of participants is attached at the end of the report along with the agenda of the meeting (Annexures 1 and 2).

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23927

